###begin article-title 0
###xml 57 62 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 126 153 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
###xml 155 160 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
To assess the relative impact of elevated T-helper 2 (TH2)- and reduced T-Helper 1 (TH1)-dependent immune responses on ocular herpes simplex virus type 1 (HSV-1) infection.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 155 160 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 352 357 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
Signal transducer and activator of transcription protein 4 knockout mice (BALB/c-STAT4-/-) and wild-type BALB/c control mice were immunized with avirulent HSV-1 strain KOS or were mock-immunized. Three weeks after the third immunization, neutralizing antibody titers were determined by plaque reduction assays. Following ocular infection with virulent HSV-1 strain McKrae, viral replication in the eye, blepharitis, corneal scarring (CS), survival, and immunoglobulin (Ig) isotypes in sera were determined.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 196 199 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 227 230 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 137 142 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 254 259 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
Vaccinated STAT4-/- and BALB/c mice contained significant and similar neutralizing antibody titers and were completely protected against HSV-1-induced death and CS. In contrast to vaccinated STAT4-/- mice, mock-vaccinated STAT4-/- mice had higher ocular HSV-1 titers than mock-vaccinated BALB/c mice on days 2-3 post-ocular infection. There were also significant differences in the levels of IgG2a, IgG2b, and IgG3 in the sera of STAT4-/- mice when compared to the control BALB/c mice.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
These results suggest that the absence of TH1 cytokine responses did alter protection against viral replication and IgG isotypes but not eye disease or survival.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 819 820 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 870 871 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 872 873 872 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 887 890 887 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 924 925 924 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 965 968 965 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 993 994 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
###xml 969 973 <span type="species:ncbi:10090">mice</span>
Signal transducers and activators of transcription (STAT) proteins are activated in response to a large number of cytokines, growth factors, and hormones [1]. Upon activation following the binding of ligands to their receptors, STAT proteins dimerize, translocate to the nucleus, and bind to the promoters of specific target genes. At present the STAT family is classified into seven groups [2] of cytoplasmic proteins, which are activated by phosphorylation of a specific tyrosine [3]. Although some cytokines and growth factors can activate multiple STAT proteins, certain STAT proteins are activated with considerable specificity. In turn, each activated STAT protein activates transcription of a specific cytokine. For example, STAT6 is involved in production of several interleukins (IL) such as IL-4 and IL-13 [4,5], while STAT4 is involved in production of IL-2 [6,7]. Thus, STAT6-/- mice have a reduced T-helper 2 (TH2)-mediated immune response, while STAT4-/- mice have an increased TH2-mediated immune response.
###end p 10
###begin p 11
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 46 47 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+</sup></bold>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 56 55 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+</sup></bold>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+</sup></bold>
###xml 208 209 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 226 227 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 226 227 226 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+</sup></bold>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 292 293 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 296 297 296 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 309 310 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 595 596 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 599 600 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 702 703 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 704 706 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 724 725 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 728 729 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 757 758 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 761 762 754 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 777 779 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 780 782 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 817 818 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 821 822 814 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 853 854 846 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 857 858 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 861 863 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 864 866 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 874 875 867 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 878 879 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 885 886 878 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 889 890 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 1018 1020 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 83 89 <span type="species:ncbi:9606">humans</span>
Following stimulation by foreign antigens, CD4+ and CD8+ T-cell clones of mice and humans produce specific patterns of cytokine expression [8,9]. Based on the cytokines produced, CD4+ T cells are designated TH1 or TH2, and CD8+ T cells are designated TC1 or TC2 [8,10,11]. Usually, either a TH1/TC1 or a TH2/TC2 cytokine pattern predominates in response to a specific antigenic challenge [12-14]. TH1/TC1 cells are involved in cellular immunity (delayed type hypersensitivity and cellular cytotoxicity) and produce IL-2, tumor necrosis factor beta (TNF-beta), and interferon-gamma (IFN-gamma). TH2/TC2 cells are involved in humoral immunity (antibody mediated) and produce IL-4, IL-5, IL-6, and IL-10 [9,15]. IL-4 enhances TH2/TC2 development and inhibits TH1/TC1 development [16,17]. IL-2 stimulates development of TH1/TC1 and inhibits development of TH2/TC2 [18,19]. The TH1/TC1 to TH2/TC2 balance determines the outcome of a wide variety of immune responses involving infectious, autoimmune, and allergic diseases [10].
###end p 11
###begin p 12
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 485 486 485 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 535 536 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 627 630 627 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 688 689 688 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 812 813 812 813 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 833 834 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 854 857 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
###xml 932 937 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
We previously demonstrated faster clearance and lower eye disease in STAT6-/- mice [20]. These results indicated that increased level of IL-2 in STAT6-/- mice was associated with improved vaccine efficacy. Immunohistochemical analyses of corneal sections of ocularly infected mice had shown that lack of protection against corneal scarring (CS) correlated with the absence of neutralizing antibody titer and the presence of IL-4 in the cornea [13,21]. Since IL-4 is an indicator of a TH2 response [8,14], these results suggested that TH2 responses are either neutral or enhance CS [13,22]. The studies presented here with STAT4-/- mice, which are deficient in IL-2 production and lack a TH1 response, were undertaken to determine if these observed correlations reflected function. We report that the absence of TH1 and elevation of TH2 responses in STAT4-/- mice had no role in protection against ocular herpes simpex virus type 1 (HSV-1) infection but did have an effect on immunoglobulin-G (IgG)-subtype switching and early viral replication.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Virus and cells
###end title 14
###begin p 15
###xml 16 21 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 66 72 <span type="species:ncbi:9986">rabbit</span>
###xml 152 158 <span type="species:ncbi:9913">bovine</span>
###xml 214 219 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
Plaque-purified HSV-1 strains (maintained in-house) were grown in rabbit skin (RS) cell monolayers in minimal essential media (MEM) containing 5% fetal bovine serum. McKrae, a stromal disease-causing neurovirulent HSV-1 strain was the ocular challenge virus. KOS, a avirulent nonstromal disease-producing strain was used as a live virus vaccine.
###end p 15
###begin title 16
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 16
###begin p 17
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
All animal procedures adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision Research and according to institutional animal care and use guidelines. Six-week-old inbred BALB/c mice and homozygous BALB/c-STAT4-/- mice (Jackson Laboratory, Bar Harbor, ME) were used in this study.
###end p 17
###begin title 18
###xml 16 20 <span type="species:ncbi:10090">mice</span>
Vaccinations of mice
###end title 18
###begin p 19
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 571 576 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
Mice were vaccinated three times intraperitoneum (IP) at 3-week intervals with 2x105 plaque-forming units (PFU) of live KOS in tissue culture media. Mock-vaccinated mice were similarly inoculated but with tissue culture media (MEM with %5 FBS) alone. Serum-neutralizing antibody titers were determined by 50% plaque reduction assays, as we described previously [23], using sera collected 3 weeks after the final vaccination. Briefly, the sera from vaccinated or mock-vaccinated mice were heat inactivated for 30 min. at 56 degreesC, diluted in MEM, mixed with 200 PFU of HSV-1 strain McKrae, and incubated for 30 min at 37 degreesC. Samples were added to RS cells in 6-well microtiter plates, the plates were incubated at 37 degreesC for 72 h, stained with 1% crystal violet, and the plaques were counted. The means of the antibody titers (50% plaque reduction) were expressed as the reciprocal of the serum dilution.
###end p 19
###begin title 20
Ocular infection
###end title 20
###begin p 21
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 142 144 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 78 83 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
Mice were infected ocularly, without corneal scarification, with 2x105 PFU of HSV-1 strain McKrae per eye, in 1 mul of tissue culture medium [23].
###end p 21
###begin title 22
Titration of virus in tears
###end title 22
###begin p 23
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Tear films were collected from both eyes of five or ten mice per group at various times, using a Dacron-tipped swab [22]. Each swab was placed in 0.5 ml tissue culture medium, squeezed, and the amount of virus was determined by a standard plaque assay on RS cells.
###end p 23
###begin title 24
Analysis of immunoglobulin subtypes and isotypes in the sera
###end title 24
###begin p 25
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
###xml 374 377 <span type="species:ncbi:10116">rat</span>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 581 592 <span type="species:ncbi:3704">Horseradish</span>
###xml 618 621 <span type="species:ncbi:10116">rat</span>
###xml 627 632 <span type="species:ncbi:10090">mouse</span>
Mice were bled by retro-orbital bleeding; sera were collected, and stored at -80 degreesC until use. IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA concentrations were determined in sera collected from vaccinated mice, using a mouse immunoglobulin isotyping enzyme-linked immunosorbent assay (ELISA) kit (Becton Dickinson, San Diego, CA). Briefly, plates were coated with different rat anti-mouse antibody isotypes and incubated at 4 degreesC overnight. Sera was then added to each well, incubated overnight at 4 degreesC and washed with 0.05% Tween in 1x phosphate-buffered saline (PBS). Horseradish peroxidase (HRP)-labeled rat anti-mouse immunoglobulin G (IgG) was incubated for 1 h at room temperature and color was developed using an enzyme substrate solution (kit provided) for 10 min at room temperature. Concentration was determined by spectrophotometric absorbance at 450 nm.
###end p 25
###begin title 26
Monitoring blepharitis and corneal scarring
###end title 26
###begin p 27
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
The severity of blepharitis and CS were scored in a masked fashion by examination with slit lamp biomicroscope following addition of 1% fluorescein as eye drops. Disease was scored on a 0 to 4 scale (0=no disease, 1=25%, 2=50%, 3=75%, and 4=100% involvement) as we described previously [24].
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Protective parameters were analyzed by the Student t test and Fisher's exact test, using Instat (GraphPad, San Diego, CA). Results were considered statistically significant when the p value was <0.05.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
###xml 0 27 <span type="species:ncbi:10298">Herpes simplex virus type 1</span>
###xml 29 34 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
Herpes simplex virus type 1 (HSV-1) neutralizing antibody
###end title 31
###begin p 32
###xml 12 15 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 425 428 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 499 507 499 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 525 526 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 659 667 659 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 687 688 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 88 93 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
BALB/c-STAT4-/- and wild-type BALB/c mice were vaccinated three times with an avirulent HSV-1 strain KOS in MEM or mock-vaccinated with MEM alone, as described in the Methods section. Three weeks after the third vaccination, sera were collected and individually heat inactivated. Neutralization titers of these sera were then determined by plaque reduction assays. The average neutralizing antibody titer for vaccinated STAT4-/- mice was not significantly different than for vaccinated BALB/c mice (Figure 1; p>0.05, Student t test). As expected, both vaccinated groups had significantly higher neutralizing antibody titers than did the mock-vaccinated mice (Figure 1; p<0.0001, Student t test).
###end p 32
###begin p 33
###xml 324 325 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 49 53 <span type="species:ncbi:10090">Mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
Neutralizing antibody titers in vaccinated mice. Mice were vaccinated three times and bled 3 weeks after the third vaccination. Neutralization titers are expressed as the reciprocal of the geometric means+/- the standard error of the mean (SEM) from seven individual mice sera. The p values were calculated from the Student t test.
###end p 33
###begin title 34
Immunoglobulin isotypes and subtypes
###end title 34
###begin p 35
###xml 105 112 105 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
Sera from vaccinated mice were analyzed for the relative expression of each Ig subtype and IgG subtypes (Table 1). No significant differences were detected between the two groups for IgG1, IgA, or IgM. However, we did detect a significant decrease in the levels of IgG2a, IgG2b, and IgG3 in the STAT4-/- mice. Thus, the absence of STAT4 altered the IgG2a, IgG2b, and IgG3 subtypes in vaccinated mice when compared with mock-vaccinated control wild-type mice.
###end p 35
###begin title 36
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Immunoglobulin isotypes in the blood of vaccinated STAT4-/- and BALB/c mice.
###end title 36
###begin p 37
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 312 315 312 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
Optical density (OD) of immunoglobulin isotypes and subtypes were determined (as described in Methods) in sera collected from five vaccinated STAT4-/- or vaccinated BALB/c mice three weeks after the third vaccination and before ocular infection. Student's t-test was used to compare results from vaccinated STAT4-/- mice to vaccinated BALB/c mice.
###end p 37
###begin title 38
Vaccine protection against lethal ocular infection
###end title 38
###begin p 39
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 239 246 239 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 367 374 367 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 100 105 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
Vaccinated and mock-vaccinated STAT4-/-and BALB/c mice were infected ocularly with 2x105 PFU/eye of HSV-1 strain McKrae, as described in the Methods section. All of the vaccinated STAT4-/- and BALB/c mice survived lethal ocular infection (Table 2). The vaccine-induced protection was highly significant for both groups compared to their mock-vaccinated counterparts (Table 2). Thus, even in the absence of STAT4, vaccination protected 100% of the mice against lethal ocular infection.
###end p 39
###begin title 40
###xml 26 31 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Survival following ocular HSV-1 infection of vaccinated mice.
###end title 40
###begin p 41
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were vaccinated three times and infected ocularly with McKrae as described in the Methods. p-Values were determined using Fisher's exact test.
###end p 41
###begin title 42
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 27 <span type="species:ncbi:10298">Herpes simplex virus type 1</span>
###xml 29 34 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Herpes simplex virus type 1 (HSV-1) ocular clearance in STAT4-/- mice
###end title 42
###begin p 43
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 202 213 202 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A,B</xref>
###xml 237 240 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 336 345 336 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A</xref>
###xml 367 370 367 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 471 480 471 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A</xref>
###xml 546 549 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 653 656 653 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 701 710 701 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2B</xref>
###xml 749 752 749 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 801 810 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2B</xref>
###xml 895 904 895 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2B</xref>
###xml 1065 1068 1065 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 61 66 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 180 185 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 287 292 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
###xml 753 757 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
###xml 853 858 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 1019 1024 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 1055 1059 <span type="species:ncbi:10090">mice</span>
Tear films from mice infected ocularly with 2x105 PFU/eye of HSV-1 (strain McKrae) were collected from 20 eyes/group on days 1-10 post infection (PI), and the amount of infectious HSV-1 was determined (Figure 2A,B). Mock-vaccinated STAT4-/- mice had no significant differences in ocular HSV-1 titers on days 1 and on days 4 thru 10 PI (Figure 2A; p>0.05), while STAT4-/- mice had significantly higher virus titers during days 2-3 PI than their corresponding BALB/c mice (Figure 2A; p<0.05); by day 4 PI, no differences were detected between STAT4-/- mice and BALB/c mice. No significant differences were detected between virus titers in vaccinated STAT4-/- mice or their corresponding BALB/c control (Figure 2B; p>0.05). However, in vaccinated STAT4-/- mice, virus was completely cleared by day 5 PI (Figure 2B). In contrast, in vaccinated BALB/c mice, HSV-1 was completely cleared by day 4 PI (Figure 2B). Thus, during early times PI in mock-vaccinated but not vaccinated mice, the absence of STAT4 appears to enhance HSV-1 replication and in vaccinated mice STAT4-/- leads to a slightly longer time to viral clearance.
###end p 43
###begin p 44
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 422 423 422 423 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 537 538 537 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 243 248 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
Virus titers in mouse eyes following ocular infection. Three weeks after the third vaccination, STAT4 knockout (STAT4-/-) (open symbols) and BALB/c mice (closed symbols) were infected ocularly, and the presence of Herpes Simplex Virus Type 1 (HSV-1) in tear films was monitored daily. For each point, the virus titer (y-axis) represents the average of the titers from 20 eyes. The error bars indicate the standard errors. A: Graph A shows virus replication in mock-vaccinated mice infected with 2x105 plaque-forming units (PFU) per eye. B: Graph B shows virus replication in KOS-vaccinated mice infected with 2x105 PFU/eye. Asterisks indicate significance (p<0.05) when titers are compared with the Student t test.
###end p 44
###begin title 45
Protection against blepharitis and corneal scarring
###end title 45
###begin p 46
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 194 185 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3A</xref>
###xml 231 234 231 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 395 404 395 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3A</xref>
###xml 548 551 548 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 760 769 760 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 789 790 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 843 846 843 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 876 885 876 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
Herpetic blepharitis was measured 7 days after ocular infection, as described in the Methods section. Vaccinated STAT4-/- and BALB/c mice were completely protected against blepharitis (Figure 3A; KOS, p>0.05). Mock-vaccinated STAT4-/- and BALB/c mice exhibited similar levels of blepharitis, and both groups had significantly higher levels of blepharitis than did their vaccinated counterparts (Figure 3A; p<0.0001). CS was measured in surviving mice on day 28 post-ocular infection, as described in the Methods section. All of the vaccinated STAT4-/- and BALB/c mice were completely protected against CS (Figure 3B; KOS, p>0.05). The protection against CS in vaccinated mice was highly significant when compared with their corresponding mock-vaccinated mice (Figure 3B; p<0.0001, Student t test). The level of CS between mock-vaccinated STAT4-/- and BALB/c mice was similar (Figure 3B; Mock, p>0.05). Thus, the absence of STAT4 did not alter the level of blepharitis or CS in either vaccinated or mock-vaccinated mice.
###end p 46
###begin p 47
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 382 389 382 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 436 437 436 437 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 490 491 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 582 583 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 169 196 <span type="species:ncbi:10298">Herpes simplex virus type 1</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
Blepharitis and corneal scarring (CS) following ocular infection. Three weeks after the third vaccination, STAT4-/- and BALB/c mice were infected infected ocularly with Herpes simplex virus type 1 neurovirulent strain McKrae. Blepharitis was measured 7 days after ocular infection based on 20 eyes, while CS was measured 28 days after ocular infection from surviving mice listed in Table 2. The error bars indicate the standard errors. A: Graph A shows blepharitis on day 7 post-infection. B: Graph B shows CS on day 28 post-infection. The p values were calculated from the Student t test.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 462 463 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 546 547 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 693 696 693 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 0 5 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 143 148 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 242 247 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 404 409 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
HSV-1 infections are among the most frequent serious viral eye infections in the USA and are a major cause of viral-induced blindness [24-29]. HSV-1-induced CS, also broadly referred to as herpes stromal keratitis, can lead to blindness, and HSV-1 is the leading cause of corneal blindness from an infectious agent in developed countries [28,30,31]. The immune response(s) leading to CS following ocular HSV-1 infection is a T-helper response, and both TH1 and TH2 have been implicated [13,32,33]. Previous work demonstrated that an increase of TH1 response leads to lesser herpetic eye disease, an increase of neutralizing antibody titers, and ultimately an expedited viral clearance in STAT6-/- knockout mice [20].
###end p 49
###begin p 50
###xml 70 73 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 125 126 125 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 232 235 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 251 254 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 310 311 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 340 341 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 640 643 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 690 693 690 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 822 825 822 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 496 501 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
The present study was designed to extend our previous study with STAT6-/- mice to determine what role, if any, elevation of TH2- and reduction of TH1-mediated immune responses may play in viral clearance and eye disease, using STAT4-/- mice. The STAT4-/- mice have impaired IL-12 processes and thus a reduced TH1 response and an increased TH2 response [34,35]. One would expect worsened eye disease in these animals, as IL-4 has been previously correlated with enhanced eye disease and increased HSV-1 replication [36,37]. However, we observed equal levels of eye disease, equal survival, and generally equal viral replication between STAT4-/- and wild-type control BALB/c mice. Also, STAT4-/- did not affect vaccine-induced protection as survival, eye disease, and viral replication were equal between the immunized STAT4-/- mice and the immunized BALB/c control mice.
###end p 50
###begin p 51
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 132 133 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 316 319 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 401 404 401 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 536 538 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 607 610 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 617 619 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 629 630 621 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 694 696 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 763 764 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 787 790 779 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 902 904 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 951 954 943 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1213 1216 1205 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1294 1297 1286 1289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1398 1400 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 1401 1403 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 1611 1613 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 1614 1616 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 1701 1704 1693 1696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1800 1802 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 1851 1854 1843 1846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1934 1936 1926 1928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1233 1237 <span type="species:ncbi:10090">mice</span>
###xml 1309 1313 <span type="species:ncbi:10090">mice</span>
###xml 1315 1321 <span type="species:ncbi:10090">Murine</span>
###xml 1352 1357 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 1446 1451 <span type="species:ncbi:9606">human</span>
###xml 1584 1589 <span type="species:ncbi:9606">human</span>
###xml 1596 1602 <span type="species:ncbi:10090">murine</span>
###xml 1705 1709 <span type="species:ncbi:10090">mice</span>
###xml 1740 1746 <span type="species:ncbi:10090">murine</span>
###xml 1855 1859 <span type="species:ncbi:10090">mice</span>
###xml 1879 1883 <span type="species:ncbi:10090">mice</span>
###xml 1928 1932 <span type="species:ncbi:10090">mice</span>
At the antibody level as we have shown here, the TH2 responses are associated with greater production of IgG1 and IgG2b, while the TH1 responses are associated with production of the IgG2a and IgG3 antibody (Ab) subclasses [38-40]. We observed a highly significant decrease in the level of IgG2a in the sera of STAT4-/- mice when compared to BALB/c control mice and to our published results with STAT6-/- mice [20]. This is most likely caused by the reduction in IFN-gamma, as this cytokine has been shown to stimulate IgG2a secretion [41], and a reduction in IFN-gamma production has been reported in STAT4-/- mice [42]. Since TH1 cells are associated with the production of IgG2a antibodies [43], our results of decreased IgG2a levels correlate with a reduced TH1 response in the STAT4-/- vaccinated mice. It was shown previously that IgG2a antibodies are associated with efficacious viral vaccines [43]. The decrease in expression of IgG2a in STAT4-/- vaccinated mice is associated with a slight reduction in vaccine efficacy. Since IgG2a is still produced, most likely due to the immunization response, there is still protection. However, this might explain the increased early viral replication seen in STAT4-/- mock-vaccinated mice as well as the delayed viral clearance observed in STAT4-/- vaccinated mice. Murine-neutralizing antibody against HSV-1 is predominantly associated with IgG2a [44-46]. Previous studies have demonstrated that human IgG1, IgG3, and IgG4 all have neutralizing ability against HSV infection, and the highest neutralizing activity was associated with human IgG1 (murine IgG2a) [47,48]. We detected a significant decrease in IgG2a and IgG2b but not in IgG1 in the STAT4-/- mice. Previously it was shown that murine IgG2a and IgG2b subtypes are able to fix complement [49]. These changes in the IgG subtypes in the STAT4-/- mice suggest that these mice have less complement than wild-type control mice [49].
###end p 51
###begin p 52
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 458 459 458 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 672 675 672 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 883 886 883 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 991 994 991 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1124 1126 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 139 144 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 679 684 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1050 1055 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 1118 1122 <span type="species:ncbi:10090">mice</span>
STAT4 responses did not appear to be involved in protection since mock-vaccinated STAT4-/- mice were not more susceptible to lethal ocular HSV-1 infection than mock-vaccinated BALB/c mice. Mock-vaccinated STAT4-/- mice had increased virus titers in their eyes on days 2 and 3 PI. However, this higher level of viral replication did not alter eye disease or survival in these mice, and it is likely that this increased viral replication was due to decreased TH1 responses. Previously we showed that an increase in IL-2 responses in the eye correlated with an increase in protection from eye disease in vaccinated mice [36,50]. The seemingly apparent lack of effect of STAT4-/- in HSV-1 infection most likely indicates immune compensation orchestrated by STAT4-independent pathways [42] or differences in response from the triggering antigen as seen during influenza infection of STAT4-/- mice [51] and in autoimmune diabetes [52]. In contrast to this study, it was previously shown that STAT4-/- mice that were ocularly infected with the RE strain of HSV-1 had exacerbated eye disease when compared with control BALB/c mice [53]. The discrepancy between this study and our own may be related to the use of different virus strains or the methods used to measure protection.
###end p 52
###begin p 53
###xml 386 387 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 152 157 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 203 208 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 430 435 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
In summary, the results presented here strongly suggest that STAT4 responses are not essential for vaccine-induced neutralizing antibody titers against HSV-1 or vaccine-induced protection against lethal HSV-1 infection. However, STAT4 responses were involved in induction of Ig subtype switching in the sera of ocularly infected mice. Taken together, our results suggest that enhanced TH1 responses are more effective in clearing HSV-1 infection, a result that mimics our previous vaccine studies [36,50].
###end p 53
###begin title 54
Acknowledgments
###end title 54
###begin p 55
This work was supported by Public Health Service grant EY13615 from the National Eye Institute to H.G.
###end p 55
###begin title 56
References
###end title 56
###begin article-title 57
Cytokine receptor signalling.
###end article-title 57
###begin article-title 58
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
###end article-title 58
###begin article-title 59
Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein.
###end article-title 59
###begin article-title 60
Jaks and Stats in signaling by the cytokine receptor superfamily.
###end article-title 60
###begin article-title 61
Stat3 and Stat4: members of the family of signal transducers and activators of transcription.
###end article-title 61
###begin article-title 62
The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.
###end article-title 62
###begin article-title 63
###xml 11 17 <span type="species:ncbi:10090">murine</span>
###xml 28 33 <span type="species:ncbi:9606">human</span>
Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis.
###end article-title 63
###begin article-title 64
###xml 13 19 <span type="species:ncbi:10090">murine</span>
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.
###end article-title 64
###begin article-title 65
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
###end article-title 65
###begin article-title 66
Functional diversity of helper T lymphocytes.
###end article-title 66
###begin article-title 67
CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
###end article-title 67
###begin article-title 68
CD4+ and CD8+ T cells acquire specific lymphokine secretion potentials during thymic maturation.
###end article-title 68
###begin article-title 69
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 165 192 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1.
###end article-title 69
###begin article-title 70
Cytokines in the generation of immune responses to, and resolution of, virus infection.
###end article-title 70
###begin article-title 71
Lymphocyte responses and cytokines.
###end article-title 71
###begin article-title 72
Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system.
###end article-title 72
###begin article-title 73
IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells.
###end article-title 73
###begin article-title 74
Acquisition of lymphokine-producing phenotype by CD4+ T cells.
###end article-title 74
###begin article-title 75
Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4- producing cells.
###end article-title 75
###begin article-title 76
###xml 22 49 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Enhanced clearance of herpes simplex virus type 1 and reduced herpetic eye disease in STAT6 knockout mice is associated with increased IL-2.
###end article-title 76
###begin article-title 77
###xml 80 107 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
###end article-title 77
###begin article-title 78
###xml 112 134 <span type="species:ncbi:10298">herpes simplex virus 1</span>
Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
###end article-title 78
###begin article-title 79
###xml 20 47 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
###end article-title 79
###begin article-title 80
Ocular herpes simplex virus infections.
###end article-title 80
###begin article-title 81
Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.
###end article-title 81
###begin article-title 82
Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group.
###end article-title 82
###begin article-title 83
Classification of herpes simplex virus keratitis and anterior uveitis.
###end article-title 83
###begin article-title 84
Herpes simplex virus epidemiology and ocular importance.
###end article-title 84
###begin article-title 85
Ocular pathogenicity of herpes simplex virus.
###end article-title 85
###begin article-title 86
New concepts in herpes simplex virus vaccine development: notes from the battlefield.
###end article-title 86
###begin article-title 87
###xml 105 110 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1.
###end article-title 87
###begin article-title 88
Developing an asymptomatic mucosal herpes vaccine: the present and the future.
###end article-title 88
###begin article-title 89
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells.
###end article-title 89
###begin article-title 90
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Impaired IL-12 responses and enhanced development of Th2 cells in Stat4- deficient mice.
###end article-title 90
###begin article-title 91
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 123 128 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge.
###end article-title 91
###begin article-title 92
The Role of Interleukin (IL)-2 and IL-4 in Herpes Simplex Virus Type 1 Ocular Replication and Eye Disease.
###end article-title 92
###begin article-title 93
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
###end article-title 93
###begin article-title 94
Lymphokine control of in vivo immunoglobulin isotype selection.
###end article-title 94
###begin article-title 95
Isotype regulation by helper T cells and lymphokines.
###end article-title 95
###begin article-title 96
IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses.
###end article-title 96
###begin article-title 97
###xml 78 95 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Identification of STAT4-dependent and independent mechanisms of resistance to Toxoplasma gondii.
###end article-title 97
###begin article-title 98
Fcgamma receptors: old friends and new family members.
###end article-title 98
###begin article-title 99
###xml 21 27 <span type="species:ncbi:10090">murine</span>
IgG2a restriction of murine antibodies elicited by viral infections.
###end article-title 99
###begin article-title 100
Mechanism of virus-induced Ig subclass shifts.
###end article-title 100
###begin article-title 101
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 33 60 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides.
###end article-title 101
###begin article-title 102
Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus.
###end article-title 102
###begin article-title 103
Herpes simplex-specific IgG subclass response in herpetic keratitis.
###end article-title 103
###begin article-title 104
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 36 42 <span type="species:ncbi:10090">murine</span>
Structure and function of human and murine receptors for IgG.
###end article-title 104
###begin article-title 105
###xml 41 46 <span type="species:ncbi:10298?0.9377676277476449">HSV-1</span>
The role of T(H)1 and T(H)2 cytokines in HSV-1-induced corneal scarring.
###end article-title 105
###begin article-title 106
Infection-triggered regulatory mechanisms override the role of STAT 4 in control of the immune response to influenza virus antigens.
###end article-title 106
###begin article-title 107
Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence.
###end article-title 107
###begin article-title 108
Role of Stat4-mediated signal transduction events in the generation of aggressor CD4+ T cells in herpetic stromal keratitis pathogenesis.
###end article-title 108

